Last week Johnson and Johnson/Centocor won it's patent law suit against Abbott concerning Humira. The jury trial concluded that adalimumab (Humira) inpinged on J&J's patent for infliximab, and awarded them 1.7 billion dollars. Apparently they felt that the fully human antibody was not adequately different from infliximab. Hard to believe that a jury is left to ponder these kind of decisions. In any case, Abbott would continue to sell their drug but would owe royalties. Given that sales of Humira in 2008 were in the order of 4.5 billion dollars, we're talking about serious cash. Not that Abbott is caving though. They're appealing the decision and counter suing J&J over Symponi, J&J's own fully human anti-TNF that is just now coming out. Could be amusing.